- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01520688
Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth
October 30, 2020 updated by: Deborah Gentile, West Penn Allegheny Health System
A Randomized, Cross Over Study Evaluating the Effect of Flovent Discus 100 mcg BID vs QVAR 80 mcg BID vs Pulmicort Flexhaler 180 mcg BID on Short Term Growth in Pediatric Subjects With Asthma
Children with mild persistent asthma that have asthma symptoms once or twice a week and use a daily controller, while children with mild intermittent asthma rarely have asthma symptoms and do not use a daily controller.
Inhaled corticosteroids are the standard treatment for mild peristent asthma.
The purpose of this study is to measure children rate of growth while on different inhaled corticosteroids.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A randomized, cross over study evaluating the effect of Flovent Discus 100 mcg BID vs QVAR 80 mcg BID vs Pulmicort Flexhaler 180 mcg BID on short term growth in pediatric subjects with asthma.
Objectives:
- The primary objective of this study is to compare the effect of Flovent Diskus 100 mcg BID versus Pulmicort Flexhaler 180 mcg BID on short-term lower leg growth velocity as measured by knemometry in pediatric subjects with mild asthma.
- The secondary objective of this study is to compare the effect of Flovent Diskus 100 mcg BID versus QVAR 80 mcg BID on short-term lower leg growth velocity as measured by knemometry in pediatric subjects with mild asthma.
Aims:
- The primary aim is to show that there is a growth suppressive effect of Pulmicort Flexhaler 180 mcg BID versus Flovent Diskus 100 mcg BID in children with mild asthma.
- The secondary aim to show that there is a growth suppressive effect of QVAR 80 mcg BID versus Flovent Diskus 100 mcg BID in children with mild asthma.
Hypotheses:
- The primary hypothesis is that treatment with Pulmicort Flexhaler 180mcg BID as compared to Flovent Diskus 100 mcg BID has a growth suppressive effect on lower leg length as assessed by knemometry in pediatric subjects with mild asthma.
- The secondary hypothesis is that treatment with QVAR 80 mcg BID as compared to Flovent Diskus 100 mcg BID has a growth suppressive effect on lower leg length as assessed by knemometry in pediatric subjects with mild asthma.
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Green Tree, Pennsylvania, United States, 15220
- Pediatric Alliance-Greentree Division
-
Pittsburgh, Pennsylvania, United States, 15212
- Allegheny General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 9 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects will include females (6 to 9 years of age) and males (6 to 11 years of age).
- All subjects must have a history of physician diagnosed mild intermittent or mild persistent asthma as documented by PCP medical record or detailed history by study investigator.
- All subjects must have a height within normal limits (5th to 95th percentile) and no history of abnormal growth as assessed by medical history.
- All subjects must be pre-pubertal (Tanner Stage 1 Sexual Maturity) as assessed by physical examination.
- Subjects may be on current treatment with montelukast as this drug does not affect growth. If a subject is on montelukast at screening/baseline, they will remain on a stable dose throughout the study.
- Subjects must be willing to comply with study requirements.
Exclusion Criteria:
- Subjects will be excluded if they have asthma greater than mild persistent severity as defined by NHLBI guidelines.
- Subjects will be excluded if they used any systemic or nasal steroids within the past 60 days.
- Subjects will be excluded if they had more than one burst of systemic steroids within the past year.
- Subjects will be excluded if their baseline FEV1 is < 80% predicted.
- Subjects will be excluded if they have any other serious systemic disease other than asthma.
- Subjects will be excluded if they have taken any medication known to affect growth i.e. ADHD medications within the past 60 days
- Subjects will be excluded if they have a history of allergy to any of the study medications, milk protein or lactose.
- Subjects will be excluded if they have active chickenpox or measles or recent exposure to chickenpox or measles.
- Subjects will be excluded if they have any history of tuberculosis of the respiratory tract.
- Subjects will be excluded if they have any active fungal, bacterial, viral or parasitic infections.
- Subjects will be excluded if they have any history of herpes simplex infection of the eye.
- Subjects will be excluded if they have taken any immunosuppressive drugs within the past 2 months.
- Subjects will be excluded if they have any history of Churg-Strauss syndrome or other eosinophilic disorders.
- Subjects will be excluded if an investigator deems they have any mental or development health issues, such as autism, moderate to severe mental retardation or severe ADHD,that interferes with their ability to complete the knemometry measurements.
- Subjects will be excluded if an investigator deems they have any physical issues, such as inability to sit independently or amputation of lower leg, that interferes with their ability to complete the knemometry measurements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1 Treatment Sequence, FPQ
Period 2 Flovent Diskus Period 4 Pulmicort Flexhaler Period 6 QVAR
|
Fluticasone 100 mcg bid Budesonide 180 mcg bid Beclomethasone 80 mcg bid
Other Names:
|
Experimental: 2 Treatment Sequence, FQP
Period 2 Flovent Diskus Period 4 QVAR Period 6 Pulmicort
|
Fluticasone 100mcg BID Beclomethasone 80 mcg BID Budesonide 180 mcg BID
Other Names:
|
Experimental: 3 Treatment Sequence, PFQ
Period 2 Pulmicort Period 4 Flovent Period 6 QVAR
|
Budesonide180 mcg BID Fluticasone 100 mcg Beclomethasone 80 mcg BID
Other Names:
|
Experimental: 4-Treatment Sequence, PQF
Period 2 Pulmicort Period 4 QVAR Period 6 Flovent
|
Budesonide 180 mcg BID Beclomethasone 80mcg BID Fluticasone 100mcg BID
Other Names:
|
Experimental: 5 Treatment Sequence, QFP
Period 2 QVAR Period 4 Flovent Period 6 Pulmicort
|
Beclomethasone 80 mcg BID Fluticasone 100mcg BID Budesonide 180 mcg BID
Other Names:
|
Experimental: 6 Treatment Sequence, QPF
Period 2 QVAR Period 4 Pulmicort Period 6 Flovent
|
Beclomethasone 80mcg BID Budesonide 180 mcg BID Fluticasone 100mcg BID
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short-term Lower Leg Growth During Treatment With Flovent Diskus 100 mcg BID or Pulmicort Flexhaler 180 mcg BID.
Time Frame: 1 yr
|
Short-term lower leg growth as assessed by knemometry in pediatric subjects with mild asthma treated with Flovent Discus 100 mcg BID or Pulmicort Flexhaler 180 mcg BID.
|
1 yr
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short-term Lower Leg Growth During Treatment With Flovent Discus 100 mcg BID or QVAR 80 mcg BID.
Time Frame: 1 yr
|
Short-term lower leg growth as assessed by knemometry in pediatric subjects with mild asthma during treatment with Flovent Discus 100 mcg BID or QVAR 80 mcg BID.
|
1 yr
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Deborah A Gentile, MD, Allegheny Singer Research Institute/Allegheny General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2012
Primary Completion (Actual)
February 1, 2016
Study Completion (Actual)
February 1, 2016
Study Registration Dates
First Submitted
January 24, 2012
First Submitted That Met QC Criteria
January 26, 2012
First Posted (Estimate)
January 30, 2012
Study Record Updates
Last Update Posted (Actual)
November 18, 2020
Last Update Submitted That Met QC Criteria
October 30, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Dermatologic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Anti-Allergic Agents
- Budesonide
- Fluticasone
- Xhance
- Beclomethasone
Other Study ID Numbers
- RC#5255
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on Fluticasone, Budesonide, Beclomethasone
-
Hamamatsu UniversityCompleted
-
Research in Real-Life LtdTeva Branded Pharmaceutical Products R&D, Inc.Completed
-
Hvidovre University HospitalRecruiting
-
Yale UniversityCompleted
-
Research in Real-Life LtdTeva Branded Pharmaceutical Products R&D, Inc.CompletedChronic Obstructive Pulmonary DiseaseUnited Kingdom
-
New York City Health and Hospitals CorporationCompletedAsthma | Pediatric ALLUnited States
-
University of VirginiaCompleted
-
Maastricht University Medical CenterAstraZeneca; Teva BrandedCompleted
-
Zhujiang HospitalUnknown
-
University Medical Center GroningenUnknown